Showing results (151-160 of 213) with videos related to
Sort By:
Pageof 22
Cell Reports|September 21, 2022
Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysisBridget P Keenan, Elizabeth E McCarthy, Arielle Ilano, et al.JCI Insight|February 27, 2025
Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4Marcel Arias-Badia, PeiXi Chen, Yee May Lwin, et al.Science Immunology|April 14, 2022
Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancerHyunwoo Kwon, Johanna M Schafer, No-Joon Song, et al.Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.Proceedings of the National Academy of Sciences of the United States of America|January 20, 2026
Functionally heterogeneous intratumoral CD4+CD8+ double-positive T cells can give rise to single-positive T cellsTony Li, Arielle Ilano, Marcel Arias-Badia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerRahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.Biorxiv : the Preprint Server for Biology|March 30, 2023
Analysis of evolutionary dynamics and clonal architecture in prostate cancerJake R Conway, Alok K Tewari, Sabrina Y Camp, et al.Cancer Research Communications|February 5, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction CancersAndrew H Ko, Joseph Chao, Marcus S Noel, et al.The Lancet. Oncology|November 3, 2023
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.Cancer Immunology Research|January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with CancerHewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.Pageof 22